Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Devices & Dosimetry

Comparison of the Efficacy of 1064- and 730-nm Picosecond Lasers for Acquired Dermal Melanocytosis

The use of a 730-nm picosecond laser, which possesses high melanin selectivity, relatively deep penetration, and a short pulse width, suggests a potentially more effective treatment for ADM, compared to the effects of the conventional 1064-nm wavelength, without increasing complications.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors retrospectively compared 730-nm and 1064-nm picosecond lasers in patients with acquired dermal melanocytosis treated between 2021 and 2024. They report that the 730-nm group had superior patient satisfaction, objective findings and software-measured melanin reduction after three sessions, with similar complication rates. The study's design is retrospective, which limits certainty about these comparative findings.

Who or what was studied
Patients with acquired dermal melanocytosis treated with picosecond laser therapy; 78 patients in the 730-nm group and 83 in the 1064-nm group
Wavelengths
730, 1064 nm
Limits stated in the abstract
The study was retrospective, and the abstract does not describe randomization or a blinded comparison.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

Acquired dermal melanocytosis (ADM) is a pigmentary lesion caused by melanocytes in the dermis. These conditions are refractory, and a consensus on treatment remains elusive.

Aims

To compare the efficacy of 730- and 1064-nm picosecond lasers in the treatment of ADM and to supplement the comparison with a literature review.

Patients

We retrospectively examined patients who underwent picosecond laser therapy between April 2021 and February 2024. Treatments were performed three times with spot irradiation using a 730-nm laser (3-mm spot, 1.7-1.8 J/cm2; or 2-mm spot, 2.5-3.25 J/cm2) and a 1064-nm laser (3-mm spot, 3.1-4.0 J/cm2). Two months after each procedure, patient satisfaction was evaluated using questionnaires, macroscopic findings were assessed using photographs, and melanin accumulation was analyzed using skin analysis software. Evaluations were conducted on a 4-point scale (excellent, good, fair, and poor), with good or higher considered effective.

Results

Seventy-eight and 83 patients were assigned to the 730- and 1064-nm groups, respectively. After three sessions, the 730-nm group exhibited superior outcomes in terms of subjective symptoms (patient satisfaction), objective findings, and software analysis improvements. The incidence of hyperpigmentation was 15.4% in the 1064-nm group and 14.5% in the 730-nm group, with no significant differences observed in the rates of other complications.

Conclusions

The use of a 730-nm picosecond laser, which possesses high melanin selectivity, relatively deep penetration, and a short pulse width, suggests a potentially more effective treatment for ADM, compared to the effects of the conventional 1064-nm wavelength, without increasing complications.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Energy density (fluence)
1.8 J/cm2, 3.25 J/cm2, 4.0 J/cm2

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Laser, Melanin, Wavelength. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies